We have generated mouse models of human Tay-Sachs and Sandhoff diseases by targeted disruption of the Hexa (α subunit) or Hexb (β subunit) genes, respectively, encoding lysosomal β-hexosaminidase A (structure, α ) and B (structure, ββ). Both mutant mice accumulate G M2 ganglioside in brain, much more so in Hexb -/-mice, and the latter also accumulate glycolipid G A2 . Hexa -/-mice suffer no obvious behavioral or neurological deficit, while Hexb -/-mice develop a fatal neurodegenerative disease, with spasticity, muscle weakness, rigidity, tremor and ataxia. The Hexb -/-but not the Hexa -/-mice have massive depletion of spinal cord axons as an apparent consequence of neuronal storage of G M2 . We propose that Hexa -/-mice escape disease through partial catabolism of accumulated G M2 via G A2 (asialo-G M2 ) through the combined action of sialidase and β-hexosaminidase B.
INTRODUCTION
Gangliosides are glycosphingolipid constituents of the outer surface of most cell membranes. They are particularly abundant in the nervous system (1-3) where they may function in neuritic growth, cell recognition, and neural transmission (4, 5) . They are catabolized in the lysosome where glycohydrolases degrade them by sequential removal of terminal sugars to a ceramide core (see Fig. 1 for nomenclature). Inherited defects of the hydrolytic enzymes cause lysosomal storage diseases in which glycolipid intermediates accumulate in the lysosome.
The G M2 gangliosidoses are autosomal recessive, lysosomal storage diseases resulting from an inability to catabolize G M2 ganglioside and related glycolipids (reviewed in ref. 6 ). The enzymatic hydrolysis of G M2 is catalyzed by β-hexosaminidase (Hex; E.C. 3.2.1.52) in the presence of a substrate-specific protein cofactor, the G M2 activator. There are two major forms of Hex: Hex A, composed of one α and one β subunit; and Hex B, composed of two β subunits. Both isoenzymes hydrolyse a broad spectrum of substrates containing terminal N-acetylglucosamine (GlcNAc) or N-acetylgalactosamine (GalNAc) residues in β-linkage (7). However, only Hex A can act on the terminal GalNAc residue of G M2 ganglioside (Fig. 1) .
There are three genetically distinct forms of G M2 gangliosidosis (6) . Tay-Sachs disease results from mutations of the HEXA gene encoding the α subunit of Hex A. It is associated with deficient Hex A activity and normal expression of Hex B. Sandhoff disease results from mutations of the HEXB gene encoding the β subunit, with resulting deficiency of both Hex A and Hex B activities. The third form does not affect the Hex activities directly but is due to G M2 activator deficiency (8, 9) . All three disorders display a similar clinical phenotype and neuropathology, except that Sandhoff disease is also associated with visceral organ pathology due to the additional Hex B deficiency. In their most severe forms, these diseases are characterized by an infantile-onset, progressive neurodegenerative disease and early death. Neurons are enlarged due to stored G M2 and related glycolipids in the lysosomal compartment, and lysosomes contain concentric membranous structures known as membranous cytoplasmic bodies (MCB) (6) .
There is no treatment for G M2 gangliosidosis. The advent of therapies based on the transfer of genes or cells into the nervous system has stimulated interest in the development of animal models of disease to enable such experiments (e.g. ref. 10) . While natural models of G M2 gangliosidosis have been described in some animals (11) (12) (13) , including Sandhoff disease in cats (14) (15) (16) , it was evident that mouse models would have the greatest potential for experimentation. We have developed mouse models of Tay-Sachs (Hexa -/-) and Sandhoff (Hexb -/-) diseases through targeted gene disruption. While both models store G M2 ganglioside in the brain, they express dramatically different phenotypes reflective of distinct abilities to respond to the accumulating lipid. Our studies point to a metabolic bypass for the degradation of stored G M2 in Hexa -/-mice and a potential for applying this knowledge to modulating G M2 storage in human Tay-Sachs disease.
RESULTS

Generation and phenotype of Hexa -/-mice
Targeting vectors were developed from previously characterized clones containing the mouse Hexa and Hexb genes (17, 18) . The construct used for targeted disruption of the Hexa gene was interrupted in exon 11 by a neomycin-resistance gene cassette ( Fig. 2A) . Nine of 153 independent CGR8 embryonic stem (ES) cell clones were identified in which one Hexa allele had incorporated the desired mutation (Fig. 2B) . Two of three clones injected into C57BL/6J blastocysts gave rise to 21 chimeric animals with ES cell contributions ranging from 5 to 95% as judged by the proportion of agouti coat color. One of eight chimeric males bred to C57BL/6J wild-type females transmitted the disrupted Hexa allele through the germline. Intercrosses between heterozygous mice produced progeny with no apparent reduction in the number of pups per litter. PCR analysis of tail biopsies (Fig. 2C) used to determine the genotype of 215 offspring of heterozygous matings gave 55 wild-type (25%), 117 heterozygous (53%) and 50 homozygous (22%) offspring at the expected Mendelian ratio (1:2:1). Hexa -/-mice showed no apparent difference in size, behavior, or reproductive ability compared with wild-type litter mates up to 1 year (Fig. 3A) .
Generation and phenotype of Hexb -/-mice
The Hexb construct contained a neomycin-resistance gene cassette inserted in exon 2 (Fig. 2D) . A total of 3/90 CGR8 and 3/110 R1 independent ES clones were confirmed to have a correct gene targeting event (Fig. 2E) . Twenty-four chimeric mice were obtained with ES cell contributions ranging from 10 to 95% as judged by the proportion of agouti coat color. Nine chimeric males were bred to C57BL/6J wild-type female and five of them (two from CGR8 and three from R1) transmitted the disrupted Hexb allele through the germline. Heterozygous Hexb +/-mice were phenotypically normal and litters resulting from intercrosses between heterozygotes were normal in size. Using PCR (Fig. 2F) , , partial map of the wild-type Hexa and Hexb mouse genes (middle line) and the mutant targeted alleles (bottom line), respectively. The genomic sequence was interrupted by a PGK-neo cassette (stippled box) at the EcoRV site of exon 11 (Hexa knockout) or at the XhoI site of exon 2 (Hexb knockout). The expected sizes of fragments hybridizing with the external (probes a and c) and internal probes (probes b and d) are indicated below the corresponding Hexa and Hexb wild-type and mutant alleles. (B and E) Genomic Southern blots of ES cell DNA. DNA from untransfected (N) and targeted ES cell clones (numbered lanes) were digested with the indicated restriction enzymes and hybridized with the indicated cDNA probes (A and D). Note that in (B), lanes 1-3 and 6-11 show correct targeting. In (E), only three clones were shown to be correctly targeted based on using both probes. (C and F) PCR analysis of mouse tail DNA from wild type (+/+), heterozygous (+/-) and homozygous (-/-) Hexa and Hexb mice. Positions of the primers (arrows 1-6) used for the PCR and the expected sizes of amplified fragments are indicated below the corresponding Hexa and Hexb wild-type and mutant alleles. M = size markers, neg = negative control. genotypic analysis of tail biopsies from 140 offspring mice showed that homozygous Hexb (-/-) mice were born at a frequency of 23%, indicating the absence of prenatal homozygous lethality.
Twenty-seven homozygous Hexb (-/-) mice (10 male, 17 female), derived from both CGR8 and two of the R1 lines, appeared healthy at birth and were indistinguishable from their normal litter mates in behavior and reproductive ability up to 3-4 months of age. However, from 111 to 147 days after birth, the affected mice became lethargic and began to show tremor, muscle weakness, stiffening of the hind limbs and an ataxic gait ( Fig.  3B-D) . Movement was slow and they had a tendency to drag the hind limbs. They were unable to right themselves when placed on their back. Weight loss became apparent, possibly due to an inability to feed (dysphagia). Preterminal symptoms included spastic quadriparesis, tremor, and myoclonus (both startle and non-startle). The disease was inevitably fatal in homozygous mice within 6 weeks of onset.
Expression of Hexa and Hexb mRNAs
Messenger RNA levels were examined in tissues from wild-type, heterozygous and homozygous mice by Northern blot using specific cDNA probes (Fig. 4) . A ∼2.2 kb Hex α transcript was detected in all tissues analyzed from wild-type and Hexa +/-mice, but was absent in Hexa -/-mice. In Hexa +/-and -/-mice, an RNA species of ∼3.2 kb was observed (Fig. 4B,C) . It was also detected with a neo probe (data not shown) and appeared to be due to a Hexa-neo fusion, presumably derived from the inclusion of all or a portion of the neomycin cassette by aberrant splicing. Hexb mRNA was undetectable in most tissues analyzed from Hexb -/-mice. An exception was testis in which a shorter transcript of 1.8 kb was observed (Fig. 4E,F) . As the neo sequence was not detected in the shorter species (data not shown), it was likely produced by exon skipping. While a very faint 1.8 kb band could also be detected in brain and epididymis (Fig. 4F) , no enzymatically active product resulted from the transcript (see below).
Analysis of Hex isoenzyme profiles
Brain and liver extracts of wild-type, Hexa -/-and Hexb -/-mice were assayed for activity toward the synthetic substrates, 4-methylumbelliferyl-β-D-N-acetylglucosamine (MUG), which is hydrolyzed by all Hex isoenzymes, and 4-MUG-6-sulfate (MUGS), which is hydrolyzed only by Hex isoenzymes containing . Hexa and Hexb RNA in tissues of wild type, Hexa -/-and Hexb -/-mice. Total RNA (10 µg) from mice of +/+, +/-, or -/-genotypes of the Hexa (upper panels) or Hexb genes (lower panels) was hybridized with cDNA probes for mouse Hexa and Hexb, respectively. After removal of the probe, the same filters were hybridized with an oligonucleotide recognizing 18S RNA. T, testis; E, epididymis; Lu, lung; Li, liver; K, kidney; H, heart; B, brain; S, spleen.
an α subunit (7). Mouse Hex A and Hex B, with similar subunit compositions as the human enzyme, behave similarly toward MUG and MUGS (19) . Both extracts from Hexa -/-mice contained approximately 50% of normal MUG activity, while MUGS activity was reduced to less than 5% in brain and less than 1% in liver (data not shown). In the Hexb -/-mice, the activity with either substrate was reduced to less than 1.5%. These data suggested that, in the Hexa -/-mouse, Hex B activity was retained while Hex A activity was reduced to near background values. In order to establish the isoenzyme distribution of the observed activity, we used chromatofocusing (20) . In the brain homogenate from a wild-type mouse (Fig. 5 , wild type), the first MUG-active enzyme to elute from the column was Hex B with a peak centered at pH 6.9 (range 7.0-6.5), followed by Hex A with a peak centered at pH 4.8 (range 5.1-4.5). Hex activity found in the region ranging from pH 5.8 to 6.1 of the elution profile may correspond to incompletely processed 'intermediate' pI forms of Hex (Hex I) (21, 22) . Analysis of the brain extract from a Hexa -/-mouse showed abundant Hex B isoenzyme eluting in the expected fractions and undetectable enzyme activity in the Hex A fractions (Fig. 5 , Hexa -/-). Brain extracts from a Hexb -/-mouse revealed negligible activity in the Hex B and Hex A fractions. Minimal activity of a third form of Hex, Hex S, an α dimer found in human Sandhoff disease (23), was recovered by step elution with sodium citrate buffer, pH 3.5 ( Fig. 5 Hexb -/-). There was also trace activity eluting at pH 4.4-4.7 that may correspond to Hex S precursor (20) . A similar chromatofocusing done with testis extracts from Hexb -/-mice had background activity, confirming that the abundant 1.8 kb β-subunit transcript did not encode a functional protein (data not shown).
Analysis of glycosphingolipids
Glycosphingolipids obtained from brain and liver were examined by HPTLC after separation into neutral and acid fractions by DEAE-Sephadex A25 chromatography. G M2 and G A2 were specifically identified and quantitated by immuno-thin layer chromatography (ITLC) using the mAb KM966 to detect G M2 ganglioside and mAb 2D4 for detection of G A2 . The HPTLC revealed the brains of wild-type mice to contain predominantly G M1 , G D1a , G D1b , G T1b and ceramide monohexosides (data not shown). In brains from Hexb -/-mice, glycolipids with the mobilities of G M2 and G A2 were detected in high abundance, while in Hexa -/-mice, only G M2 was elevated (Fig. 6A,B) . Quantitation by ITLC showed that Hexb -/-mice brains contained G M2 over 10-20× elevated and G A2 8-50× elevated (Fig. 6C ). In contrast, in the Hexa -/-mice, brain G M2 was elevated only 6-10× control values and G A2 was within normal range.
In the liver of normal mice, G M2 was the major ganglioside, while G A2 was very low or below the limit of detection. No significant change in the level of G M2 was observed in Hexa -/-(unchanged) or Hexb -/-(1-3× elevation; Fig. 6C ). However, Hexb -/-but not Hexa -/-mice contained G A2 about 10-30× the level detected in normal mice. Thus, the Hexa -/-mice accumulated neither of these lipids in liver.
Tissue and cellular analysis
Macroscopic examination of the brain of Hexa -/-and Hexb -/-mice revealed a normal appearance. However, light microscopy of semi-thin sections (0.5 µm thick) of cerebral cortex revealed neurons with clusters of perinuclear inclusions in both the Hexa -/-and Hexb -/-mice. Ultrastructurally, the inclusions were similar to MCB observed in the human diseases. They varied from concentric to parallel membranous arrays to crescentshaped inclusions and amorphous structures (Fig. 7A,B) .
The nerve fibers of both the dorsal and ventral roots appeared normal in Hexa -/-and Hexb -/-mice. In contrast, dramatic structural differences between the Hexa -/-and Hexb -/-mice were observed in the spinal cord. While the morphology of the spinal cord appeared normal in the Hexa -/-mice (Fig. 8C) , a gross depletion of nerve tracts was observed along the length of the spinal cord in the Hexb -/-mice (Fig. 8B) . In the latter, the density of axons was diminished throughout the lateral tracts and anterior funiculus, with many of the remaining fibers showing abnormalities consistent with the recent loss of axonal integrity including collapsed myelin sheaths (Fig. 8D,E) . These abnormalities did not extend to the posterior funiculus which appeared largely normal with myelinated axons present in abundance. Anterior horn cells and other cell bodies throughout the gray matter showed extensive vacuolation or presence of storage granules. In the semi-thin sections of the dorsomedial gray matter, a large number of darkly stained, vesicle-engorged structures, without an evident nucleus, were identified (Fig. 8F) . Electron microscopy showed remnants of enlarged myelinated structures filled with MCB (Fig. 8G) .
Examination of visceral organs revealed no morphological abnormalities in the Hexa -/-mouse (Fig. 7D,G) . In contrast, the liver and kidney of the Hexb -/-mouse showed extensive structural alterations. In the liver, parenchymal cells contained large cytoplasmic vacuoles (Fig. 7E ). Kupffer and endothelial cells also presented large aggregations of dense bodies and vacuoles. In the kidney, the cytoplasm of epithelial cells lining the proximal tubules showed extensive vacuolation (Fig. 7H) . Renal corpuscles, distal convoluted tubules and collecting ducts appeared normal.
G M2 ganglioside immunohistochemistry
The distribution of G M2 ganglioside was determined by immunohistochemistry using mAb KM966. In normal brain, G M2 was undetectable, except in rare cells. In Hexa -/-brains, G M2 showed a specific and limited distribution, although staining could be very intense in positive neurons. Coronal sections of Hexa -/-brain showed G M2 immunostaining in the septal area, hippocampus and the pyramidal layer of the cerebral cortex. Intense staining was observed in a thin band of cells, layer 6b, at the base of the cortex (Fig. 9A) . Staining was observed in scattered cells of the basal ganglia, and the thalamus and hypothalamus showed sparse to heavy staining in different regions with intense staining of the lateral mammillary nucleus (Fig. 9B) . The cerebellum was unstained (Fig. 9C ) except at the tip of one lobule (the simple lobule, not shown). The brainstem showed a single site of intense staining in the large cells of the mesencephalic nucleus of the 5th nerve. The cell bodies of the spinal cord, including anterior horn cells, did not show G M2 ganglioside immunostaining (Fig. 9D) .
In Hexb -/-mice, G M2 ganglioside storage was far more extensive and widely distributed. Coronal sections of the Hexb -/-mice showed immunostaining of essentially all areas that were positive in the Hexa -/-brain but much more so. For example, the immunostaining in the cerebral cortex now extended from the pyramidal cells of layer 5 through to the base of the cortex (Fig. 9E) . The more intensely stained cells also showed staining of their processes. Strongly stained areas included the somatosensory area of the cerebral cortex, thalamus, septal region, striatum, globus pallidus, hippocampus (CA3 and dentate gyrus), the substantia nigra pars compacta and the supramammillary region including the lateral mammillary nucleus (Fig. 9E,F) .
The greatest differences in the distribution of G M2 were in the cerebellum, brainstem and spinal cord. While the Hexa -/-brain was almost clear of immunostaining in the cerebellum, the Hexb -/-mice showed very extensive staining within the granular layer (Fig. 9G) . This staining appeared to define a horizontal compartment parallel to the Purkinje cell layer, a pattern not normally identified with functional compartmentalization in the cerebellum (24) . Where these cells were heavily stained, projections appearing to emanate from the cell bodies were also stained. At higher magnification, faint staining could also be detected in Purkinje cells but not with the intensity observed in the granular cells. Despite the extensive ganglioside storage, no obvious structural abnormalities were noted (Fig. 9G) . In Hexa -/-mice, the brainstem and spinal cord were devoid of staining except in rare cells, whereas, in Hexb -/-mice, extensive staining was observed in neurons throughout both regions (Fig. 9H) . In Hexa -/-mice, the large motor neurons of the anterior horns were unstained in contrast to Hexb -/-mice which showed intense staining in cell bodies and associated processes (Fig. 9H) .
Significantly, G M2 storage was undetectable by immunostaining in a 2 week old Hexb -/-mouse and was barely detectable, mainly in anterior horn cells and cells of the brainstem, in a 2½ week old mouse (data not shown).
DISCUSSION
The mutant mice we have produced appear to be valid models of G M2 gangliosidosis. Hexa -/-mice lack Hex A activity and Hexb -/-mice lack both Hex A and Hex B activity. Both accumulate G M2 ganglioside and have characteristic lysosomal inclusions in neuronal cells. However, unlike the human disease, Hexa -/-mice have no behavioral phenotype, while Hexb -/-mice express a rapidly progressive, fatal neurodegenerative disease. Our observations on Hexa -/-mice are similar to those reported by Proia and colleagues who also produced a Hexa -/-mouse by gene targeting (25, 26) . While the mutant we generated was disrupted by an insertion in exon 11, theirs was disrupted by an insertion in exon 8. The phenotype expressed by the two independently derived Hexa -/-mice confirms the benign nature of a complete deficiency of Hex A activity in mice. The similarity of the G M2 ganglioside distribution in the brains of the two Hexa -/-mice and the much greater accumulation in Hexb -/-mice suggest that the fundamentals of ganglioside biology are similar in mice and humans. Consequently, the disease avoidance in Hexa -/-mice must be due to the single biochemical difference between the two mice, the retention of Hex B activity in the Hexa -/-mouse.
The striking progression of the neurodegenerative process in our two independently derived (CGR8 and R1) lines of Hexb -/-mice parallels the rapid downhill course of human Tay-Sachs or Sandhoff disease (6). In both, the newborn appears healthy. Muscle weakness and lack of purposeful movement appear as early symptoms and both progress to an immobile, unresponsive state. Tremor, ataxia, spasticity and muscle weakness are features of later onset, more slowly progressive forms of the human disease that we observed in Hexb -/-mice. The absence of G M2 storage in the brain of Hexb -/-mice in the first weeks after birth readily explains the absence of early symptoms. In humans, the first appearance of MCB in the anterior horn cells of the spinal cord was in a fetus with Tay-Sachs disease at 12 weeks of gestation (27) . In a similar manner, in a Hexb -/-mouse, G M2 storage was first detected in anterior horn cells observed 2-3 weeks post-natally.
The remarkable extent of axon damage, the extensive vacuolation of neurons in the gray matter including motor neurons, and the large, MCB-engorged axon remnants in the spinal cord are sufficient to explain the fatal nature of the Hexb -/-disease. These pathological findings suggest that the integrated circuitry of the spinal cord is disrupted at multiple levels, leading to total incoordination of somatic motor systems. While the extensive storage of G M2 ganglioside in the basal ganglia, cerebellum and cerebral cortex may also have contributed to the observed symptoms, we do not yet know the extent to which intact neurons, swollen with G M2 storage bodies, are able to function.
The quantitative analysis of brain and liver glycosphingolipids provides support for a threshold model of G M2 toxicity. First, there was 1.5-3 times the level of G M2 in the brains of a Hexb -/-compared with Hexa -/-mice. These results were consistent with the relatively low intensity of immunostaining in the brain of Hexa -/-mice. Further, as G A2 is derived by catabolism of G M2 , the total storage is more aptly represented by G M2 + G A2 . It equalled 440-1452 nmol/g wet weight of Hexb -/-brain, in striking contrast to the 194 and 234 nmol/g wet weight total storage obtained in the two Hexa -/-brains. The critical, toxic threshold may reside between these two ranges, as it is not known whether G A2 also contributes to neuron dysfunction. Accumulated G M2 has been shown to induce ectopic sprouting of neurites in cortical pyramidal cells (28) and may also affect neurotransmitter function (29) .
A plausible hypothesis to explain disease progression is that G M2 slowly accumulates in neurons without a detectable influence on behavior in the affected animal. Once the critical threshold is achieved, abnormalities of neuronal structure and function are induced that result in subsequent disintegration of axons and, perhaps, cell bodies in spinal cord and presumably in brain. As the severity of the nerve tract depletion increases, the affected mice begin to show an overt phenotype which manifests itself as motor dysfunction. After 3-4 months of unremarkable behavior, the mice enter a rapid phase that leads to complete immobilization within 6 weeks of the first appearance of symptoms.
Our combined data suggest that the Hexa -/-mice escape disease by keeping the G M2 stores to below toxic levels. The presence of the Hex B isoenzyme offers a compelling clue to a mechanism for metabolic sparing in these mice. Two models for partial metabolism of G M2 are envisioned (Fig. 1) . In Model 1, Hex B acts directly on G M2 to convert it to G M3 , which is further catabolized by sialidase to Lac-Cer. This model would readily explain the absence of symptomatic disease in Hexa -/-mice. However, it would also imply that the substrate specificity of Hex B was different in mice and humans, as, in the latter, Hex B shows no activity toward G M2 (30) . In early studies on the G M2 activator, Burgh et al. (31) demonstrated that mouse brain extracts from which Hex A was removed could release GalNac from G M2 , suggesting to them that Hex B in combination with the G M2 activator could act on G M2 . These experiments were done using 3 H-G M2 labelled in the GalNAc moiety so that it was not possible to distinguish the direct action of Hex B from a combined action of sialidase followed by Hex B. Further, mouse and human Hex B behave similarly toward synthetic substrates that distinguish Hex A and Hex B activity (19) , as confirmed in Figure 5 . The trace activity of MUGS toward Hex B in Figure 5 is consistent with a high K m for MUGS, as determined for the human enzyme (7). Thus, it is unlikely that a sparing effect of Hex B could occur through direct action of the enzyme on G M2 .
According to Model 2 ( Fig. 1) , sialidase acts on G M2 to convert it to G A2 , which is further degraded by Hex B to Lac-Cer. The activity of sialidase toward G M2 is not normally favored owing to the more potent activity of Hex A toward G M2 (6) . However, in the absence of Hex A due to mutation in the Hexa -/-mouse, partial catabolism via G A2 appears to be prominent. Although lysosomal sialidase is only weakly active toward G M2 (32, 33) and Hex B hydrolyses GalNAc from G A2 at only ∼3% the activity of Hex A (30), there is nonetheless a several-fold higher level of G A2 in autopsy brains of Sandhoff vs Tay-Sachs patients (34) . We surmise that the difference in the Hexa -/-mouse that allows it to escape disease is a more efficient conversion of G M2 to G A2 than occurs in the human disease. An example of a functioning sialidase-mediated G M2 catabolic pathway is found in the mouse neuroblastoma line Neuro2a. Riboni et al. (35) treated Neuro2A cells with 3 H-G M2 labelled in the sphingosine moiety and showed that the principal metabolites were G A2 and Lac-Cer. A similar incubation with 3 H-G M1 also resulted in catabolism through G A2 .
Our data favor Model 2. In the absence of Hex B in Hexb -/-mice, stored G A2 is derived directly from G M2 . In the Hexa -/-mouse, the same conversion of G M2 to G A2 occurs but, in this instance, the G A2 is more rapidly cleared due to the presence of Hex B, driving the reaction toward further catabolism.
At the completion of this investigation, Proia and colleagues (36) reported a Hexb -/-mouse generated by targeted disruption of exon 13 of the Hexb gene. They describe a similar behavioral phenotype with onset at about 3 months after birth. Glycolipid storage was demonstrated with periodic-acid-Schiff (PAS) in almost all neurons of the central nervous system. They ascribed the motor deficit in their mice to the prominence of storage neurons in areas such as the cerebellum and spinal cord. It is not known if their mice also demonstate the marked depletion of axons of the spinal cord, which we believe is more directly compatible with the very rapid course of the disease. They went on to examine 3 H-G M1 catabolism in embryonic fibroblasts cultured from Hexa -/-and Hexb -/-mice and demonstrated the dominance of the G A2 pathway (Model 2), even in normal cells. They concluded that the mouse sialidase has a much greater affinity for G M2 than the human enzyme, making the capacity to escape disease in the Hexa -/-mouse a unique property of this mouse model. It remains to be seen whether the G A2 bypass occurs due to an intrinsic property of sialidase, as they suggest, or to an increased level of sialidase activity. The results of this investigation highlight the pharmacologic modulation of brain sialidase levels as a potential therapeutic strategy for human Tay-Sachs disease. Specifically, inducing sialidase to higher specific activity could result in the more efficient conversion of G M2 to G A2 and consequent continued catabolism via Hex B. If this is the mechanism conferring the benign phenotype in the mouse, it seems possible that infants treated shortly after birth could also maintain G M2 at subtoxic levels and escape symptomatic disease.
MATERIALS AND METHODS
Construction of replacement vectors
To construct the targeting vector, pHA12neo ( Fig. 2A) , a 1.7 kb SmaI-HindIII fragment which included exons 11-13 of the mouse Hexa gene (17) was subcloned in pBluescript (Stratagene). A 1.8 kb EcoRI-XbaI fragment containing the neomycinresistance (neo r ) gene controlled by the phosphoglycerate kinase-1 (pgk) promoter (PGKneobpA; 37), kindly provided by Dr J. Rossant, Toronto, Canada, was blunted with Klenow and inserted into the unique EcoRV site in exon 11, disrupting the coding sequence at base pair 1216 (corresponding to the Hexa cDNA; 38). The neo r cassette was subcloned in the same transcriptional orientation as the genomic sequences. A 5.2 kb HindIII-SalI fragment containing exon 14 and the 4.8 kb BstI-SmaI fragment containing exons 6-10 were subcloned upstream and downstream of exons 11-13, respectively.
To construct the targeting vector, pHexb11.3neo (Fig. 2D) , a 5.6 kb ClaI-KpnI fragment containing exons 1 and 2 of the mouse Hexb gene (18) was subcloned into pBluescript. The 1.8 kb neo r expression cassette was inserted into a blunted, unique XhoI site in exon 2 disrupting the coding sequence at base pair 346 (corresponding to the Hexb cDNA; 39). Finally, a 5.7 kb KpnI-SmaI fragment which contains exons 3-5 of the mouse Hexb gene was included at the 3′ end of the construct.
Transfection and selection of mutant ES cells
The CGR8 ES line, kindly provided by Dr William C. Skarnes, Edinburgh, UK), and the R1 ES line (40) were grown on 0.1% gelatin-coated culture dishes in medium as described, except that the R1 line included the use of irradiated early passage mouse primary embryonic fibroblasts (feeders) (40) . Twenty µg of the targeting constructs, linearized with Not1, were used to transfect 2×10 7 ES cells in 800 µl of cold PBS using a Bio-Rad GenePulser (240V, 500 µF). After the electroporations, cells were seeded at varying dilutions in ES culture medium and G418 (180 µg/ml; Geneticin, GIBCO) was applied 24 h after transfection. After 7-10 days, G418-resistant clones were isolated, resuspended and plated into two wells, one for freezing down and the other for DNA analysis (41) . Genomic DNA (10 µg) from individual ES clones was digested to completion with BamH1 (Hexa knockout) or EcoRV or KpnI (Hexb knockout) and analyzed by Southern blot. The hybridization cDNA probes were a 156 bp 5′-flanking fragment (Hexa knockout; Fig. 2 , probe 'a') or a 202 bp 3′-flanking fragment (Hexb knockout; Fig. 2 , probe 'c') containing sequences not included in the targeting vectors. Clones identified as being heterozygous for the desired homologous recombination event were further analyzed by Southern blot using internal cDNA probes ( Fig. 2 ; probes 'b' and 'd').
Generation of mutant mice
The generation of chimeric mice from Hexa or Hexb targeted ES cells were performed as previously described (42) . Newborn pups were identified as chimeric on the basis of agouti coat color. Highly chimeric males were crossed at 6 weeks of age with C57BL/6J females. Germline transmission was scored on the basis of agouti coat color of F 1 pups. Heterozygotes were interbred to produce homozygous offspring. Mutant gene transmission was confirmed by Southern blot analysis of mouse tail DNA.
Genotyping of mice
PCR typing of tail DNA was performed as shown schematically in Figure 2 . Primers for detection of Hexa sequences were: primer 1, 5′-GGCCAGATACAATCATACAG and primer 2, 5′-CTG-TCCACATACTCTCCCCACAT; and for Hexb were, primer 4, 5′-GGTTTCTACAAGAGACATCATGGC and primer 5, 5′-CA-ATCGGTGCTTACAGGTTTCATC. Primers for detection of the PGKneo vector sequences were primer 3, 5′-CACCAAAG-AAGGGAGCCGGT in the pgk promoter and primer 6, 5′-GA-TATTGCTGAAGAGCTTGGCGGC in neo. These primers (final concentration of 0.5 µM) were added to a PCR buffer containing 20 mM Tris (pH 8.4), 50 mM KCl, 1.5 mM MgCl 2 , 0.2 mM dNTPs, 2.5 units Taq DNA polymerase (GIBCO) and 2 µl of genomic DNA. The PCR samples (total volume, 100 µl) were preheated at 95_C for 5 min. Thirty-five PCR cycles were performed composed of 20 s denaturation at 94_C, 20 s annealing at 57_C, and 1 min extension at 72_C. The products (16 µl) were analyzed on a 2% agarose gel.
Northern blot analysis
Total cellular RNA was prepared from various mouse tissues including testis, epididymis, lung, liver, kidney, heart, spleen and total brain and analyzed by Northern blot as described previously (17, 18) . The hybridization probes from the Hexa and Hexb cDNA contained the entire coding sequences. A 600 bp fragment from the neomycin-resistance gene was used to detect the neo sequence, and a synthetic oligonucleotide recognizing 18S ribosomal RNA was used to assess equivalence of loading between lanes.
Chromatofocusing and enzyme assays
Proteins were isolated from total brain and liver from Hexa and Hexb +/+ and -/-mice. Tissues were homogenized in 5 vol (wt/vol) of cold 0.025 M imidazole (pH 7.4). The homogenates were alternately frozen-thawed three times, briefly sonicated on ice and spun down at 12 000 g for 10 min at 4_C. Aliquots containing 1 OD 280 of total soluble protein were applied to a chromatofocusing column at 4_C containing the Polybuffer Exchanger (PBE 94, Pharmacia Fine Chemicals) as described elsewhere (20) . Hex activity of each fraction was determined as described (43) , using 3 mM MUG (SIGMA) and MUGS (Toronto Research Chemicals). The fluorescence was determined in an LS 50 Luminescence Spectrometer (Perkin Elmer) with the excitation wavelength at 360 nm and the emission wavelength at 447 nm. The pH of each fraction was also determined.
Monoclonal antibodies
The murine mAb 2D4 recognizing G A2 was obtained from ATCC (ATCC TIB 185). The mouse/human chimeric IgG1 antibody KM966 recognizing G M2 ganglioside was prepared as described (44) . HRP-conjugated-goat antihuman IgG (γ) was from BioSource International, FITC-conjugated goat F(ab′) 2 anti-human IgG were obtained from Southern Biotechnology Associates and HRP-conjugated rabbit antimouse IgM was from Zymed Laboratories.
Glycosphingolipid extraction and quantitation
Glycosphingolipids were extracted, purified and characterized as described in detail earlier (45, 46) . In brief, murine tissues (0.1-0.5 g wet weight) were extracted with chloroform/methanol solvents. Following saponification, the glycosphingolipids were fractionated into neutral and acid glycolipids by DEAE-Sephadex A-25 chromatography. Glycosphingolipids were separated into individual components by HPTLC on Si-60 plates (E. Merck) in solvents chloroform/acetone 1:1 v/v (pre-run) followed by chloroform/methanol/water 65:25:4 v/v (neutral glycosphingolipids) and chloroform/methanol/0.2% CaCl 2 55:45:10 v/v (gangliosides). Neutral glycosphingolipids were visualized with orcinol/H 2 SO 4 and gangliosides with resorcinol/HCl. G M2 and G A2 were identified by immune thin layer chromatography using mAbs to G M2 (KM966 5 µg IgG/ml) and G A2 (2D4, supernatant 1:2 diluted), with purified bovine brain G A2 and G M2 (Alexis Corp., San Diego, CA) as standards and diaminobenzidine as chromogen. G M2 and G A2 were quantitated by fluorescence immune thin-layer chromatography using antibody KM966 (5 µg IgG/ml) or 2D4 (supernatant diluted 1:2) and FITC-conjugated antihuman IgG or antimouse IgM antibody and a fluor image analyzer (FluoroImager 575, Molecular Dynamics). The quantitations were made within the linear range of calibration curves determined for authentic standards (data not shown).
Light and electron microscopy and immunohistochemistry
Mice were anesthetized with sodium pentobarbital and tissues were perfused-fixed through the heart with 2.5% glutaraldehyde buffered in sodium cacodylate (0.1 M) containing 0.5% CaCl 2 (pH 7.4). Brain, liver, kidneys and spleen were removed and placed in the same fixative for 1 h at 4_C. Following fixation and washing in 0.1 M cacodylate buffer the tissues were postfixed in ferrocyanide-reduced osmium for 1 h at 4_C, dehydrated in a graded ethanol series and embedded in Epon (47) . Semi-thin sections (0.5 µm thick) were cut and stained with toluidine blue and examined under the light microscope. Thin sections (65 nm thick) were mounted on slotted copper grids, stained with uranyl acetate and lead citrate and examined with an electron microscope.
For immunohistochemical detection of G M2 ganglioside in tissue sections, anesthetized mice were perfused through the heart with freshly made 4% paraformaldehyde. Following perfusion, brain and spinal cord were removed and further fixed in the same fixative overnight at 4_C. The samples were rinsed briefly in 0.1 M phosphate-buffered saline, dehydrated in 0.5 M sucrose solution and snap frozen in chilled isopentane. Tissues were stored at -80_C. For immunohistochemical staining, 10-15 µm frozen sections were cut in a cryostat and collected on to poly-L-lysine coated slides. The sections were post-fixed in 4% paraformaldehyde for 10 min and rinsed in Tris-buffered saline (TBS). Endogenous peroxidase activity was blocked with 0.3% H 2 O 2 in methanol for 30 min and rinsed in TBS. The slides were treated with 0.1% Triton X-100 in TBS, followed by 1.5% bovine serum albumin solution. The slides were incubated with the KM966 antibody diluted to 1/600 in TBS for 1 h at room temperature in a humidified chamber. They were rinsed, incubated with biotinylated goat antihuman IgG antibody diluted to 1/200 in TBS for 30 min, rinsed, incubated with ABC reagent (Vector Laboratories) for 30 min and developed in diaminobenzidine. The slides were counterstained with haematoxylin, dehydrated through ethanol and xylene and mounted in permount.
